Status | Study |
Active, not recruiting |
Study Name: Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis Condition: Glomerulonephritis Focal Segmental Glomerulosclerosis Date: 2017-04-16 |
Recruiting |
Study Name: Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients Condition: Kidney Transplantation Focal Segmental Glomerulosclerosis (FSGS Date: 2016-09-30 Interventions: Drug: Bleselumab Intravenous i |
Recruiting |
Study Name: Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis Condition: Glomerulosclerosis, Focal Segmental Renal Insufficiency, Chroni Date: 2016-01-30 Interventions: Biological: Autologous Cell Transplantation Endovascular infusion of bone marrow derived cells in both r |
Recruiting |
Study Name: Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS Condition: Idiopathic Focal Segmental Glomerulosclerosis Date: 2015-12-15 Interventions: Drug: Acthar 80 U 2x/week Acth |
Recruiting |
Study Name: Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) Condition: Focal Segmental Glomerulosclerosis Date: 2015-03-03 Interventions: Biological: Intravenous injection Intravenous injection of AD-MSC to the patients with FSGS |
Recruiting |
Study Name: Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children Condition: Focal Segmental Glomerulosclerosis 1 Date: 2014-09-06 Interventions: Device: Liposorber® LA-15 System Liposorber® LA-15 System is an extracorporeal blood purificat |
Completed |
Study Name: A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) Condition: Glomerulosclerosis, Focal Segmental Date: 2013-11-27 Interventions: Drug: Losmapimod Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, |
Completed |
Study Name: A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) Condition: Primary Focal Segmental Glomerulosclerosis Date: 2012-08-13 Interventions: Drug: fresolimumab 1 mg/kg tot |
Active, not recruiting |
Study Name: Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis Condition: Focal Segmental Glomerulosclerosis Date: 2012-06-04 Interventions: Drug: RE-021 (Sparsentan) Oral |
Recruiting |
Study Name: A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS Condition: Primary Focal Segmental Glomerulosclerosis Date: 2012-04-05 Interventions: Biological: Rituximab Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 |